linjc16/ctgov huggingface dataset:
Skin Diseases and Pregnancy: Which Heathcare Professionals ?

Study Overview
=================
Brief Summary
-----------------
Pregnancy-induced physiological dermatological changes are common. In 2016, they represented between 23% (acne) and 75% (pigmentary changes) of pregnancies in France. Some dermatological changes require medical advice to identify a possible pathological rash. These pathological rashes can be dangerous for the mother or the fetus. The aim of this study is to assess the prevalence of skin diseases during pregnancy and to evaluate the care pathway in a healthcare sector (Vendee) for these pregnant women?

Detailed Description
-----------------
Pregnancy-induced physiological dermatological changes are common. In 2016, they represented between 23% (acne) and 75% (pigmentary changes) of pregnancies in France. Some dermatological changes require medical advice to identify a possible pathological rash. These pathological rashes can be dangerous for the mother or the fetus. It is therefore essential to recognize them for a quick specialized treatment. They include: intrahepatic cholestasis of pregnancy, pemphigoid gestationis, polymorphic eruption during pregnancy, atopic eczema, generalized pustular psoriasis in pregnancy. In view of the demography of dermatologists in the Vendee, 18 dermatologists in 2020 in all establishments (hospitals, clinics, practices), the general practitioner is at the center of these considerations. The aim of this study is to assess the situation of skin disease during pregnancy and to evaluate the care pathway in a healthcare sector (Vendee) for these pregnant women?

Official Title
-----------------
Skin Diseases: Which Heathcare Professionals do Pregnant Women in Vendee Use?

Conditions
-----------------
Skin Abnormalities, Pregnancy

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any woman who gives birth at Departmental Hospital Center of Vendee Exclusion Criteria: Patient's refusal to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|Self-questionnaire on skin diseases reported during pregnancy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify the health care provider that pregnant women consult when experiencing a skin disease | Type of health care provider seeing a pregnant woman for skin disease | after delivery during the patient's stay in the maternity (2-3 days) |
Safety and Efficacy of Ultrasound Guided Vascular Access

Study Overview
=================
Brief Summary
-----------------
Vascular access involves central and peripheral vein accesses and arterial accesses. Central venous catheterization is widely used in clinical practice for diverse purposes, including hemodialysis for end stage renal failure, invasive hemodynamic monitoring, radiological studies, infusion of drugs that cannot be administered via peripheral vessels, administration of parenteral nutrition, vascular access in patients whose peripheral veins are difficult to be catheterized and for miscellaneous purposes that require access to large caliber vessels. Arterial cannulation is used for invasive arterial pressure monitoring and to ensure access for diagnostic and therapeutic interventions. In the United States and United Kingdom, guidelines have recommended the use of ultrasound guidance to reduce complications and improve success in central venous catheterization.

Official Title
-----------------
Safety and Efficacy of Ultrasound Guided Vascular Access

Conditions
-----------------
Vascular Access, Ultrasound Guided Vascular Access

Intervention / Treatment
-----------------
* Device: ultrasound guided vascular access


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: · Adult patients who need vascular access (arterial or venous) Exclusion Criteria: · Patients with local infection in the area targeted for vascular access. Patients with severe generalized infection and other skin diseases or lesions. patients with history of DVT of the target vein and or pulmonary embolism. Patients with untreated coagulopathy (INR >1.5 or platelets <50000mm3)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patients need vascular access<br>Arterial or venous cathetrization guided by ultrasound | Device: ultrasound guided vascular access<br>* Arterial or venous catheterization guided by ultrasound<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse effects of ultrasound guided vascular access | Number of participants with adverse effects after ultrasound guided vascular access | one year |
Effect of Moderate Alcohol Consumption to Cognitive Functioning After Roux-en Y Gastric Bypass

Study Overview
=================
Brief Summary
-----------------
Objectives: Alcohol metabolism is changed in gastric bypass patients, leading to faster resorption and higher alcohol peak concentrations in blood. Because of stronger alcohol effects after gastric bypass we suggest that also general cognitive function is stronger impaired. Materials and Methods: We included 28 females (12 gastric bypass patients, 8 obese and 8 normal weight subjects) in the study. Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510.

Conditions
-----------------
Bariatric Surgery, Alcohol Consumption, Cognitive Function

Intervention / Treatment
-----------------
* Behavioral: 250 ml alcohol consumption


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gastric bypass group: women preOP BMI >35 kg/m² time since bariatric surgery > 1 year age 18-60 years moderate drinking habits obese group: women BMI >35 kg/m² age 18-60 years moderate drinking habits normal weight group: women BMI 18.5 - 25 kg/m² age 18-60 years moderate drinking habits Exclusion Criteria: men patient does not drink wine usage of psychotropic drugs alcoholic pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 250 ml alcohol consumption<br>Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510. | Behavioral: 250 ml alcohol consumption<br>* Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in reaction time after alcohol consumption |  | Change measures (baseline, 10 min, 45 min) |
Effectiveness of Local Application of Warm Air in Patients With Common Cold (HELI Study)

Study Overview
=================
Brief Summary
-----------------
In a randomized controlled trial, the investigators include patients with beginning symptoms of a common cold and compare two interventions: the inhalation of warm air for inducing a warming of the throat and the inhalation of ambient air as control. As outcome the effect on symptoms and duration of the common cold will be assessed. The interventions will consist of visits with a duration of 2-3 minutes on three following days in a Finnish sauna. Patients will be fully dressed.

Official Title
-----------------
Effectiveness of Local Application of Warm Air in Patients With Common Cold (HELI Study)

Conditions
-----------------
Common Cold

Intervention / Treatment
-----------------
* Procedure: inhalation of warm air in a Finnish sauna
* Procedure: inhalation of ambient air in a Finnish sauna


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptom duration between 2 and 24 hours at least two of the ten following symptoms: cough, headache, hoarseness, muscle ache, nasal drainage, nasal congestion, scratchy throat, sore throat, sneezing, and fever no usage of medication bought in a pharmacy informed consent Exclusion Criteria: fever >38.5°C systolic blood pressure below 100 mmHg or above 160 mmHg severe chronic disease, which makes study participation impossible pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Procedure: inhalation of warm air in a Finnish sauna<br>* three times on three following days, each 2-3 minutes<br>|
| Sham Comparator: 2<br> | Procedure: inhalation of ambient air in a Finnish sauna<br>* three times on three following days, each 2-3 minutes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom Score for Common Cold |  | Area under the curve day 2 to 7 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usage of medication against common cold |  | Day 1 to 7 | 
| generalized feeling ill on a numeric rating scale 0-10, |  | Day 1, 2, 3, 5 and 7 | 
| safety (adverse events and serious adverse events) |  | 1 to 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
common cold, Finnish sauna, rct
Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)

Study Overview
=================
Brief Summary
-----------------
In this study, effects of γδT cells on human breast cancer (her2-, er-,pr-) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.

Detailed Description
-----------------
Breast tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as immunotherapy.

Official Title
-----------------
γδ T Cell Immunotherapy for Treatment of Breast Cancer

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Biological: DC-CIK
* Biological: γδ T Cell
* Biological: Combination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age:18-75 Karnofsky performance status >50 Diagnosis with breast tumors based on histology or the current accepted radiological measures. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ Will receive cryosurgery, gd Tcells/ DC-CIK. Life expectancy: Greater than 3 months Ability to understand the study protocol and a willingness to sign a written informed consent document Exclusion Criteria: Patients with other kinds of cancer History of coagulation disorders or anemia Patients with heart disease and diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>DC-CIK cells will be used against tumor cells. | Biological: DC-CIK<br>* DC-CIK cells will be used against tumor cells.<br>|
| Experimental: Group B<br>γδ T cells will be used against tumor cells. | Biological: γδ T Cell<br>* γδ T cells will be used against breast tumor.<br>|
| Experimental: Group C<br>Combination of γδ T cells/ DC-CIK be used against tumor cells. | Biological: Combination<br>* γδ T/DC-CIK cells will be used against breast tumor.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduced size of the tumors |  | Up to one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
γδ T Cell, breast cancer, her2-, er-, pr-
Clinical Relevance of the Reverse Lipopolysaccharide Transport Pathway in Patients With Acute Peritonitis

Study Overview
=================
Brief Summary
-----------------
When there is infection in the intra-abdominal area, bacteria secrete toxins that are absorbed by the peritoneum. These toxins then bind to lipoproteins (which carry cholesterol in the blood) and are eliminated by the liver. Phospholipid transfer protein (PLTP) is a protein that facilitates the binding of bacterial toxins to lipoproteins and thus their elimination. The objective of this study is to study the relationship between PLTP and the elimination of bacterial toxins in humans. A better understanding of the elimination of these toxins will lead to a better understanding of the disease. The ultimate objective is to improve the management of intra-abdominal infections.

Official Title
-----------------
Clinical Relevance of the Reverse Lipopolysaccharide Transport Pathway in Patients With Acute Peritonitis An Observational Prospective Study

Conditions
-----------------
Peritonitis

Intervention / Treatment
-----------------
* Biological: blood samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: person who has given oral consent (patient or family member) pre-operative SEPSIS criteria (qSOFA >=2) or vasopressor or mechanical ventilation treatment admitted to the operating room for suspected generalized secondary peritonitis Exclusion Criteria: person not affiliated to national health insurance person under legal protection (curatorship, guardianship) person under court order pregnant, parturient or breastfeeding woman minor immunosuppression (HIV infection, corticosteroid treatment > 0.15 mg/kg/day prednisolone equivalent > 2 weeks, immunosuppressive treatment, primary cellular immune deficiency) decision to limit or stop therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with suspected peritonitis<br>Secondary peritonitis, sepsis and endotoxemia | Biological: blood samples<br>* 4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perioperative plasma concentration in 3HM |  | 24 hours postoperatively |
Platelet-rich Plasma for Menical Tear

Study Overview
=================
Brief Summary
-----------------
Meniscal injuries are a common pathology among athletes, and have an impact on the daily or sporting practice of patients. Surgical approach implies sometimes heavy consequences. Platelet-rich-plasma (PRP) has been shown to be effective in accelerating wound healing and tissue regeneration in orthopedic and oral surgery. This clinical trial aims to investigate the safety and efficacy of intraarticular and periferal PRP injection in patients with stable meniscal injury. The pre- and post-interventional clinical outcomes will be compared.

Official Title
-----------------
Platelet-rich Plasma for Menical Tear

Conditions
-----------------
Platelet-Rich Plasma, Meniscus Lesion

Intervention / Treatment
-----------------
* Procedure: Platelet-rich plasma (PRP) therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Skeletally mature patients 18-70 years of age With diagnosis of meniscus injury Single tear of the medial and/or lateral meniscus With no indication of meniscus repair surgery Exclusion Criteria: Prior history of multiple ligaments injury, associated significant ligament instability: Grade III MCL, Grade III PCL, or ACL deficient knee Prior history of knee surgery Discoid meniscus Osteoarthritic changes (Kellgren Lawrence scale >2) Inflammatory diseases (i.e. rheumatoid arthritis) Underlying bleeding disorder or coagulopathy Concominant chondral defects (> 2 ICRS) Cancer patients Pregnancy Patients who will not cooperate with six-month followup

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee injury and Osteoarthritis Outcome Score scale |  | 6months post procedure | 
| Visual Analog Scale |  | 6months post procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| International Knee Documentation Committee - Subjective Knee Evaluation Form |  | 6months post procedure | 
| Satisfaction Level |  | 6months post procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Growth factors, Meniscal injury
Making the Most of Mealtimes Determinants of Food Intake

Study Overview
=================
Brief Summary
-----------------
M3 is a multi-site cross sectional study. Data were collected form 640 residents in 32 homes in Canada. The primary purpose of this study was to identify food intake in residents and compare this to recommendations, as well as determine influential determinants of food intake.

Detailed Description
-----------------
This cross-sectional study has collected in-depth data at the resident, dining room, staff, and home level, focused on determinants of food intake. Dietary intake is based on three non-consecutive days of weighed and estimated food intake. Oral health and dyshphagia risk are assessed. Person directed care practices, mealtime environments and home level variables of food cost, production and delivery are ascertained.

Official Title
-----------------
Making the Most of Mealtimes (M3): Determinants of Food Intake in Long Term Care

Conditions
-----------------
Malnutrition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: medically stable living in selected units, residing in home for more than one month consent to participate Exclusion Criteria: considered end of life by staff; tube feeding

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Malnutrition | Subjective Global Assessment | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
food intake